Semprus raises $8 million in series A financing
Semprus is the developer of a new technology platform aimed at reducing medical device complications in areas of infections, thrombus, restenosis and bone integration. The company has previously
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
The objectives of the double-blind, randomized, placebo-controlled multiple dose Phase Ib study were to determine safety and tolerance when adding ALX-0081 via intravenous administration to a standard anti-thrombotic
BridgeGate has granted Healthation a non-exclusive license to incorporate the BridgeGate integration platform within Healthation’s AcceleHealth real-time benefit management system and AboveHealth EHealth suite. Healthation’s AcceleXchange, an integration